| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Follicular | 51 | 2023 | 587 | 13.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 57 | 2024 | 1664 | 6.930 |
Why?
|
| Lymphoma, Non-Hodgkin | 23 | 2024 | 1039 | 4.420 |
Why?
|
| Immunotherapy, Adoptive | 41 | 2024 | 1763 | 3.720 |
Why?
|
| Lymphoma, B-Cell | 15 | 2023 | 895 | 3.390 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 11 | 2023 | 301 | 3.180 |
Why?
|
| Rituximab | 40 | 2024 | 1528 | 2.760 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 65 | 2024 | 15862 | 2.430 |
Why?
|
| Antigens, CD19 | 29 | 2024 | 577 | 2.280 |
Why?
|
| Lymphoma | 11 | 2024 | 1467 | 1.950 |
Why?
|
| Lymphoma, Mantle-Cell | 11 | 2022 | 713 | 1.650 |
Why?
|
| Piperidines | 10 | 2023 | 1035 | 1.510 |
Why?
|
| Antineoplastic Agents | 21 | 2023 | 14289 | 1.450 |
Why?
|
| Adenine | 8 | 2023 | 631 | 1.410 |
Why?
|
| Hodgkin Disease | 11 | 2020 | 1429 | 1.140 |
Why?
|
| Humans | 195 | 2024 | 261506 | 1.100 |
Why?
|
| Antibodies, Bispecific | 3 | 2023 | 246 | 1.040 |
Why?
|
| Biphenyl Compounds | 2 | 2023 | 194 | 1.020 |
Why?
|
| Morpholines | 2 | 2023 | 289 | 1.000 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2023 | 10035 | 0.960 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 11 | 2020 | 864 | 0.950 |
Why?
|
| Pyridones | 2 | 2023 | 348 | 0.940 |
Why?
|
| Biological Products | 11 | 2024 | 274 | 0.930 |
Why?
|
| Stem Cell Transplantation | 7 | 2022 | 1360 | 0.930 |
Why?
|
| Benzamides | 4 | 2023 | 1832 | 0.920 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 7 | 2023 | 181 | 0.910 |
Why?
|
| Exanthema | 2 | 2023 | 211 | 0.910 |
Why?
|
| Maintenance Chemotherapy | 4 | 2018 | 202 | 0.860 |
Why?
|
| Central Nervous System Neoplasms | 7 | 2023 | 502 | 0.810 |
Why?
|
| Cyclophosphamide | 17 | 2023 | 3001 | 0.780 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 | 2023 | 2390 | 0.770 |
Why?
|
| Vincristine | 14 | 2023 | 1511 | 0.770 |
Why?
|
| Pyrimidines | 6 | 2021 | 3518 | 0.770 |
Why?
|
| Recurrence | 15 | 2023 | 4758 | 0.770 |
Why?
|
| Adult | 82 | 2024 | 77950 | 0.740 |
Why?
|
| Aged | 72 | 2024 | 70117 | 0.730 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2020 | 86 | 0.720 |
Why?
|
| Molecular Targeted Therapy | 8 | 2021 | 2330 | 0.700 |
Why?
|
| Models, Biological | 2 | 2018 | 3254 | 0.690 |
Why?
|
| Mediastinal Neoplasms | 3 | 2018 | 423 | 0.680 |
Why?
|
| Prednisone | 12 | 2023 | 984 | 0.670 |
Why?
|
| Doxorubicin | 19 | 2023 | 3005 | 0.670 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2023 | 1146 | 0.660 |
Why?
|
| Leukemia, Lymphoid | 1 | 2019 | 276 | 0.660 |
Why?
|
| Middle Aged | 77 | 2024 | 86204 | 0.660 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2018 | 63 | 0.630 |
Why?
|
| Disease-Free Survival | 24 | 2021 | 10001 | 0.630 |
Why?
|
| Safety | 1 | 2019 | 465 | 0.590 |
Why?
|
| Immunologic Factors | 2 | 2020 | 649 | 0.580 |
Why?
|
| Interferons | 2 | 2020 | 291 | 0.570 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 229 | 0.570 |
Why?
|
| Survival Rate | 21 | 2022 | 12221 | 0.570 |
Why?
|
| Positron-Emission Tomography | 7 | 2022 | 2173 | 0.560 |
Why?
|
| Female | 85 | 2024 | 141928 | 0.560 |
Why?
|
| Male | 79 | 2022 | 123000 | 0.550 |
Why?
|
| Quinazolines | 1 | 2021 | 923 | 0.550 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1870 | 0.550 |
Why?
|
| Treatment Outcome | 37 | 2023 | 32848 | 0.540 |
Why?
|
| Bendamustine Hydrochloride | 3 | 2023 | 107 | 0.530 |
Why?
|
| Aged, 80 and over | 37 | 2024 | 29902 | 0.510 |
Why?
|
| Positron Emission Tomography Computed Tomography | 8 | 2023 | 833 | 0.500 |
Why?
|
| Neoplasm Staging | 25 | 2020 | 13658 | 0.490 |
Why?
|
| Pyrazoles | 4 | 2020 | 1471 | 0.480 |
Why?
|
| Disease Management | 8 | 2021 | 1052 | 0.480 |
Why?
|
| Imatinib Mesylate | 1 | 2018 | 1665 | 0.470 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2021 | 6207 | 0.470 |
Why?
|
| Watchful Waiting | 1 | 2016 | 289 | 0.460 |
Why?
|
| Prognosis | 26 | 2024 | 21713 | 0.460 |
Why?
|
| Radiotherapy | 8 | 2020 | 1824 | 0.460 |
Why?
|
| Cell- and Tissue-Based Therapy | 6 | 2023 | 406 | 0.460 |
Why?
|
| Neoplasms, Second Primary | 4 | 2023 | 1350 | 0.450 |
Why?
|
| Young Adult | 30 | 2024 | 21445 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 8 | 2021 | 4367 | 0.450 |
Why?
|
| Retrospective Studies | 40 | 2023 | 37905 | 0.410 |
Why?
|
| Immunotherapy | 6 | 2023 | 3341 | 0.410 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2022 | 113 | 0.410 |
Why?
|
| Radioimmunotherapy | 3 | 2020 | 119 | 0.400 |
Why?
|
| Combined Modality Therapy | 14 | 2021 | 8865 | 0.400 |
Why?
|
| Health Status Disparities | 1 | 2014 | 291 | 0.390 |
Why?
|
| Salvage Therapy | 9 | 2021 | 2054 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 2359 | 0.370 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2022 | 387 | 0.370 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2019 | 2104 | 0.360 |
Why?
|
| Breast Implants | 3 | 2022 | 391 | 0.360 |
Why?
|
| Retreatment | 3 | 2020 | 452 | 0.350 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1048 | 0.350 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 2291 | 0.350 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 15694 | 0.340 |
Why?
|
| Survival Analysis | 15 | 2021 | 9180 | 0.340 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2024 | 6550 | 0.330 |
Why?
|
| United States | 21 | 2024 | 15433 | 0.330 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 3251 | 0.330 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2019 | 119 | 0.320 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 14889 | 0.320 |
Why?
|
| Standard of Care | 2 | 2020 | 243 | 0.310 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2023 | 1678 | 0.300 |
Why?
|
| Breast Implantation | 2 | 2022 | 228 | 0.290 |
Why?
|
| Neoplasm Grading | 5 | 2019 | 1742 | 0.290 |
Why?
|
| Neutropenia | 3 | 2021 | 968 | 0.290 |
Why?
|
| Remission Induction | 6 | 2023 | 3569 | 0.290 |
Why?
|
| Mitoxantrone | 2 | 2017 | 216 | 0.280 |
Why?
|
| Organs at Risk | 2 | 2020 | 514 | 0.280 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 2864 | 0.280 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2023 | 103 | 0.270 |
Why?
|
| Etoposide | 5 | 2018 | 870 | 0.270 |
Why?
|
| Dexamethasone | 3 | 2021 | 1450 | 0.260 |
Why?
|
| Radiotherapy Dosage | 5 | 2020 | 3842 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 3 | 2021 | 125 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 7551 | 0.260 |
Why?
|
| Lymphoma, T-Cell | 2 | 2019 | 361 | 0.250 |
Why?
|
| Transplantation, Autologous | 6 | 2022 | 1914 | 0.250 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 4988 | 0.250 |
Why?
|
| Comorbidity | 5 | 2023 | 2352 | 0.250 |
Why?
|
| Medicare | 4 | 2023 | 860 | 0.240 |
Why?
|
| Insurance Coverage | 2 | 2018 | 256 | 0.240 |
Why?
|
| Prospective Studies | 7 | 2023 | 12873 | 0.230 |
Why?
|
| Disease Progression | 6 | 2021 | 6682 | 0.230 |
Why?
|
| Leukapheresis | 2 | 2022 | 152 | 0.230 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2022 | 1226 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 1248 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 224 | 0.220 |
Why?
|
| Environmental Exposure | 2 | 2016 | 288 | 0.220 |
Why?
|
| Adolescent | 20 | 2024 | 31252 | 0.220 |
Why?
|
| Thrombocytopenia | 4 | 2022 | 846 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2020 | 5178 | 0.210 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 22 | 0.200 |
Why?
|
| Signal Transduction | 4 | 2020 | 11965 | 0.200 |
Why?
|
| Autografts | 2 | 2018 | 165 | 0.200 |
Why?
|
| Depsipeptides | 2 | 2019 | 78 | 0.200 |
Why?
|
| Burkitt Lymphoma | 2 | 2022 | 335 | 0.200 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 15 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2019 | 2218 | 0.200 |
Why?
|
| Hepatitis B | 1 | 2024 | 258 | 0.200 |
Why?
|
| SEER Program | 8 | 2018 | 1000 | 0.190 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 23 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2023 | 191 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 4938 | 0.190 |
Why?
|
| Machine Learning | 1 | 2023 | 319 | 0.190 |
Why?
|
| Histiocytosis | 1 | 2020 | 54 | 0.190 |
Why?
|
| Pyrazines | 2 | 2021 | 495 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 1249 | 0.190 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2023 | 366 | 0.190 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 306 | 0.190 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2020 | 15 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 4757 | 0.180 |
Why?
|
| Diarrhea | 2 | 2022 | 686 | 0.180 |
Why?
|
| Organizational Policy | 1 | 2020 | 73 | 0.180 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2020 | 49 | 0.180 |
Why?
|
| Lymphocytes | 3 | 2022 | 1234 | 0.180 |
Why?
|
| CREB-Binding Protein | 1 | 2020 | 86 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2022 | 199 | 0.180 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 245 | 0.180 |
Why?
|
| Dura Mater | 1 | 2019 | 73 | 0.180 |
Why?
|
| Neoplasms | 7 | 2024 | 15193 | 0.170 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 299 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 598 | 0.170 |
Why?
|
| T-Lymphocytes | 5 | 2023 | 3869 | 0.170 |
Why?
|
| Immunomodulation | 1 | 2020 | 242 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 3719 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 528 | 0.160 |
Why?
|
| Stomach Neoplasms | 3 | 2020 | 2278 | 0.160 |
Why?
|
| Population Surveillance | 3 | 2016 | 627 | 0.160 |
Why?
|
| B-Lymphocytes | 3 | 2024 | 1294 | 0.160 |
Why?
|
| Bortezomib | 2 | 2017 | 543 | 0.160 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2019 | 63 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 544 | 0.150 |
Why?
|
| Hepatitis B, Chronic | 1 | 2019 | 137 | 0.150 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 365 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 538 | 0.150 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2017 | 15 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 665 | 0.150 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2018 | 132 | 0.150 |
Why?
|
| Quality of Life | 2 | 2024 | 4532 | 0.150 |
Why?
|
| Thalidomide | 3 | 2015 | 569 | 0.150 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.150 |
Why?
|
| Treatment Failure | 2 | 2018 | 1391 | 0.150 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2020 | 612 | 0.150 |
Why?
|
| Hazardous Substances | 1 | 2016 | 27 | 0.140 |
Why?
|
| Mutation | 7 | 2022 | 15179 | 0.140 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2016 | 70 | 0.140 |
Why?
|
| Testicular Neoplasms | 2 | 2018 | 529 | 0.140 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 565 | 0.140 |
Why?
|
| Infection Control | 1 | 2018 | 270 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 2403 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2018 | 204 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 810 | 0.140 |
Why?
|
| beta 2-Microglobulin | 1 | 2016 | 184 | 0.140 |
Why?
|
| Patient Selection | 2 | 2022 | 2055 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2020 | 1014 | 0.140 |
Why?
|
| Research | 1 | 2018 | 415 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Cohort Studies | 8 | 2024 | 9244 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 482 | 0.130 |
Why?
|
| Leukemia, B-Cell | 1 | 2016 | 117 | 0.130 |
Why?
|
| Observation | 1 | 2015 | 48 | 0.130 |
Why?
|
| Resorcinols | 1 | 2015 | 27 | 0.130 |
Why?
|
| Time Factors | 5 | 2021 | 12926 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2018 | 498 | 0.130 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 112 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2019 | 1544 | 0.130 |
Why?
|
| Central Nervous System | 3 | 2023 | 436 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2016 | 684 | 0.130 |
Why?
|
| Gastric Mucosa | 1 | 2019 | 613 | 0.130 |
Why?
|
| Fever | 1 | 2018 | 497 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 317 | 0.130 |
Why?
|
| Isoxazoles | 1 | 2015 | 81 | 0.120 |
Why?
|
| Breast | 2 | 2018 | 1344 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 247 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 524 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 446 | 0.120 |
Why?
|
| Biomarkers | 4 | 2019 | 5047 | 0.120 |
Why?
|
| Mammaplasty | 1 | 2022 | 780 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 222 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2019 | 492 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 242 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 907 | 0.120 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 923 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 451 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 698 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 196 | 0.120 |
Why?
|
| Induction Chemotherapy | 2 | 2014 | 669 | 0.120 |
Why?
|
| Benzene | 1 | 2013 | 45 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2018 | 554 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 260 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 441 | 0.120 |
Why?
|
| Animals | 7 | 2024 | 59536 | 0.110 |
Why?
|
| Registries | 2 | 2018 | 2170 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2015 | 193 | 0.110 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 301 | 0.110 |
Why?
|
| Vinblastine | 3 | 2020 | 453 | 0.110 |
Why?
|
| Bleomycin | 3 | 2020 | 467 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 4320 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 4892 | 0.110 |
Why?
|
| Multimodal Imaging | 2 | 2017 | 550 | 0.110 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 1946 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 788 | 0.110 |
Why?
|
| Vidarabine | 1 | 2017 | 1341 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Neutrophils | 1 | 2016 | 835 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Dacarbazine | 3 | 2020 | 485 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 1 | 2019 | 767 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2022 | 211 | 0.100 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2011 | 51 | 0.100 |
Why?
|
| Carcinoma | 1 | 2023 | 2578 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1959 | 0.100 |
Why?
|
| Heart | 1 | 2018 | 1223 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2021 | 3472 | 0.100 |
Why?
|
| Antigens, CD20 | 2 | 2022 | 206 | 0.100 |
Why?
|
| Drug Design | 1 | 2013 | 375 | 0.100 |
Why?
|
| Incidence | 6 | 2018 | 5673 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2020 | 1823 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 945 | 0.100 |
Why?
|
| Research Design | 1 | 2018 | 1544 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2195 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4744 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 2796 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3230 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 1303 | 0.080 |
Why?
|
| Bone Marrow | 3 | 2023 | 2358 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2020 | 726 | 0.080 |
Why?
|
| Ifosfamide | 2 | 2018 | 344 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 598 | 0.070 |
Why?
|
| Biopsy | 3 | 2019 | 3443 | 0.070 |
Why?
|
| Drug Resistance | 2 | 2018 | 587 | 0.070 |
Why?
|
| Yttrium Radioisotopes | 2 | 2020 | 178 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 2594 | 0.070 |
Why?
|
| United States Environmental Protection Agency | 2 | 2016 | 12 | 0.070 |
Why?
|
| Georgia | 2 | 2016 | 53 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 2803 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 5539 | 0.060 |
Why?
|
| Carboplatin | 2 | 2018 | 823 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1586 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 5112 | 0.060 |
Why?
|
| Social Class | 2 | 2018 | 310 | 0.060 |
Why?
|
| HIV Infections | 1 | 2016 | 2134 | 0.060 |
Why?
|
| Lung | 1 | 2015 | 3151 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 7548 | 0.060 |
Why?
|
| Polyamines | 1 | 2022 | 75 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 2 | 2020 | 3976 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2024 | 185 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2022 | 6869 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 6915 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2024 | 217 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 5159 | 0.050 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 1022 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2022 | 246 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2022 | 135 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 10331 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 151 | 0.050 |
Why?
|
| Drug Substitution | 1 | 2021 | 87 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 249 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4849 | 0.050 |
Why?
|
| Canada | 1 | 2021 | 429 | 0.050 |
Why?
|
| Sample Size | 1 | 2021 | 202 | 0.050 |
Why?
|
| Germinal Center | 1 | 2021 | 161 | 0.050 |
Why?
|
| Forecasting | 1 | 2023 | 694 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2020 | 46 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 462 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2021 | 161 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2022 | 604 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 182 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 94 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2023 | 1144 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2022 | 582 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2019 | 130 | 0.040 |
Why?
|
| Risk Factors | 4 | 2018 | 17523 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2020 | 284 | 0.040 |
Why?
|
| Orbital Neoplasms | 1 | 2020 | 224 | 0.040 |
Why?
|
| Algorithms | 2 | 2023 | 3890 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2019 | 2967 | 0.040 |
Why?
|
| Methotrexate | 1 | 2022 | 999 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 124 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 904 | 0.040 |
Why?
|
| Ilium | 1 | 2018 | 54 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 175 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 11538 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 233 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 279 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2022 | 1681 | 0.040 |
Why?
|
| Histone Acetyltransferases | 1 | 2020 | 411 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2020 | 434 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2024 | 1439 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 30 | 0.040 |
Why?
|
| Child | 1 | 2018 | 29154 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2024 | 1230 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 57 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 292 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 181 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 1290 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 2370 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2992 | 0.030 |
Why?
|
| Orbit | 1 | 2017 | 205 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2017 | 242 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2020 | 769 | 0.030 |
Why?
|
| Abortion, Induced | 1 | 2016 | 91 | 0.030 |
Why?
|
| Cytarabine | 1 | 2022 | 1973 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 755 | 0.030 |
Why?
|
| Quinazolinones | 1 | 2015 | 51 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 2843 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 259 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 992 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2146 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 175 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 1493 | 0.030 |
Why?
|
| Mycoses | 1 | 2018 | 386 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2016 | 251 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 2018 | 479 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 166 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.030 |
Why?
|
| Topotecan | 1 | 2014 | 239 | 0.030 |
Why?
|
| Purines | 1 | 2015 | 273 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 91 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2014 | 102 | 0.030 |
Why?
|
| Edema | 1 | 2015 | 267 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1411 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 4654 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 358 | 0.030 |
Why?
|
| Radiometry | 1 | 2018 | 980 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4314 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2018 | 834 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 1859 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 1546 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 393 | 0.030 |
Why?
|
| Life Style | 1 | 2015 | 612 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1972 | 0.020 |
Why?
|
| Medicaid | 1 | 2014 | 279 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2020 | 1295 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2012 | 371 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 1216 | 0.020 |
Why?
|
| Mice | 2 | 2024 | 34495 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2307 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1053 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 589 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 250 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 2231 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1390 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 1756 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2016 | 1863 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2015 | 1171 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1301 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3981 | 0.020 |
Why?
|
| Fatigue | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1245 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 3343 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3890 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 1996 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2020 | 7226 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 6100 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3570 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 2139 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2020 | 5270 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 5377 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 14551 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3022 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7573 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 4821 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8873 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 7702 | 0.010 |
Why?
|